Selvita (WSE:SLV) Third Quarter 2024 Results
Key Financial Results
- Revenue: zł89.5m (up 6.4% from 3Q 2023).
- Net income: zł2.42m (up from zł4.27m loss in 3Q 2023).
- Profit margin: 2.7% (up from net loss in 3Q 2023). The move to profitability was primarily driven by higher revenue.
All figures shown in the chart above are for the trailing 12 month (TTM) period
Selvita Earnings Insights
Looking ahead, revenue is forecast to grow 16% p.a. on average during the next 3 years, compared to a 11% growth forecast for the Life Sciences industry in Europe.
Performance of the market in Poland.
The company's shares are up 4.3% from a week ago.
Valuation
Our analysis of these results suggests Selvita may be undervalued based on 6 important criteria we look at. Discover what analysts are forecasting and how the current share price shapes up by clicking here.
New: Manage All Your Stock Portfolios in One Place
We've created the ultimate portfolio companion for stock investors, and it's free.
• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About WSE:SLV
Very undervalued with solid track record.
